BioHarvest Sciences

BioHarvest Sciences

BioHarvest Sciences was founded in 2007 and operates from Vancouver, Canada, with its core research and manufacturing footprint anchored in Rehovot, Israel. Ilan Sobel, a former Unilever and Mondelez executive, joined as CEO in 2019 and repositioned the technology platform toward direct-to-consumer nutraceuticals and functional foods. The company is not a family office or asset manager in the traditional sense — it is an operating business that has attracted crossover interest from institutional allocators and life-science specialists because its biotech approach to commodity molecules redefines supply chains. Dr. Yochi Hagay, a plant-cell biologist, heads the technology team that built the proprietary Bio-Plant CELLicitation platform. The company deploys capital into expanding its bioprocessing capacity, with a current focus on scaling its 20-ton-per-year bioreactor facility in Israel (per the company, 2023). Its technology grows the full-spectrum phytocomplex of a plant — not just a single extracted compound — directly in liquid suspension, without a field or a plant stem. The platform currently produces VINIA, derived from grape cells, and the company has publicly disclosed a product pipeline that includes olive-cell formulations for metabolic health, cannabis cells for therapeutic molecules, and hops cells for the brewing industry. The olive-cell product entered commercialization preparation in early 2025. The company's partnership with Tate & Lyle, announced in late 2023, validates its B2B model: supplying functional botanical ingredients at food-grade scale without the environmental footprint of conventional agriculture. The company trades on the TSX Venture Exchange and last reported a market capitalization below C$100 million, making it a micro-cap with an outsized IP portfolio. In January 2025, the firm appointed a new board member with deep pharmaceutical commercialization experience, signaling intent to pursue medical-food and therapeutic-channel sales alongside the existing direct-to-consumer e-commerce model. The company's current revenue base is small — under C$20 million annually as of its latest filings — but growing at triple-digit percentage rates year-over-year through its Amazon storefront and dedicated subscription offering. Institutional ownership includes a mix of life-science crossover funds and retail shareholders. Structurally, BioHarvest differs from nearly every other ag-tech or precision-fermentation company in one specific way: it grows whole plant cells, not yeast-derived single proteins or extracts. Competitors in the synthetic-biology space — such as Amyris or Ginkgo Bioworks — engineer microbes to produce target molecules. BioHarvest's bioreactors cultivate actual plant cells that naturally assemble the full matrix of polyphenols, flavonoids, and fibers found in the original fruit or leaf. This yields a product that is not a purified additive but a whole-food ingredient produced under pharmaceutical conditions. The company has spent over a decade and the bulk of its raised capital defending this patent estate across the US, Europe, and Israel.